Histone deacetylase (HDAC) inhibitors shift HDAC‐histone acetyl transferase equilibria in all cells, tumor and immune cell alike, to alter chromatin frameworks and consequent expression profiles. This evidence concerns the gene HDAC9 and neoplasm.